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Directed Evolution Strategies for Enantiocomplementary
Haloalkane Dehalogenases: From Chemical Waste to
Enantiopure Building Blocks
Jan G. E. van Leeuwen,[a] Hein J. Wijma,[a] Robert J. Floor,[a] Jan-Metske van der Laan,[b] and
Dick B. Janssen*[a]
Introduction
Directed evolution is a valuable tool for tailoring of naturally
occurring enzymes for specific biocatalytic applications. In con-
trast with rational protein redesign, which is directed towards
structure-based construction and testing of small numbers of
enzyme variants, directed evolution focuses on the generation
of libraries with large genetic diversity and subsequent discov-
ery of improved variants by selection or screening.[1] Iterative
cycles of mutagenesis and/or recombination of beneficial mu-
tations, with selection or screening for improved properties,
can produce highly useful biocatalysts.[2–4] Various enzyme
properties such as thermostability,[2] resistance to organic sol-
vents,[2] pH optimum,[2] substrate scope,[3] and enantioselectivi-
ty[1c,d, 4] have been successfully targeted with directed evolu-
tion. New tools and strategies directed towards reduction of
the experimental work required for a successful directed evolu-
tion project are continuously being developed. One important
goal is to minimize the screening effort that is required to
obtain a desired enzyme by designing libraries with high abun-
dances of improved variants.[1d,5]
Established methods to introduce genetic diversity in direct-
ed evolution libraries include various implementations of mu-
tagenic PCR, oligonucleotide-assisted mutagenesis, and in vitro
recombination under mutagenic conditions.[6] Sequence satura-
tion mutagenesis (SeSaM[10]) at random positions may also be
used. If it is assumed that most mutations are deleterious or
neutral, construction of mutant libraries by random methods
such as error-prone PCR and random saturation mutagenesis is
inefficient when the enzyme properties that it is desired to im-
prove are mainly determined in a small part of the enzyme,
such as the active site. To focus saturation mutagenesis at
promising regions and to obtain libraries with high abundan-
ces of desired variants, methods such as iterative CASTing
(combinatorial active site test) and ISM (iterative saturation
mutagenesis) were explored by Reetz and co-workers.[7] Struc-
tural information is used to select residues that shape the
active site and that are expected to influence substrate scope
and enantioselectivity. The selected target positions are sub-
jected to mutagenesis in a systematic fashion and this process
is repeated until variants with the desired properties are ob-
tained.
In oligonucleotide-assisted mutagenesis, it is also desirable
to develop methods that suppress uneven distribution of sub-
stitutions resulting from the fact that some amino acids are
specified by larger numbers of different triplets than others.
This codon bias effect can be reduced by applying partly de-
We used directed evolution to obtain enantiocomplementary
haloalkane dehalogenase variants that convert the toxic waste
compound 1,2,3-trichloropropane (TCP) into highly enantioen-
riched (R)- or (S)-2,3-dichloropropan-1-ol, which can easily be
converted into optically active epichlorohydrins—attractive in-
termediates for the synthesis of enantiopure fine chemicals. A
dehalogenase with improved catalytic activity but very low
enantioselectivity was used as the starting point. A strategy
that made optimal use of the limited capacity of the screening
assay, which was based on chiral gas chromatography, was de-
veloped. We used pair-wise site-saturation mutagenesis (SSM)
of all 16 noncatalytic active-site residues during the initial two
rounds of evolution. The resulting best R- and S-enantioselec-
tive variants were further improved in two rounds of site-re-
stricted mutagenesis (SRM), with incorporation of carefully se-
lected sets of amino acids at a larger number of positions, in-
cluding sites that are more distant from the active site. Finally,
the most promising mutations and positions were promoted
to a combinatorial library by using a multi-site mutagenesis
protocol with restricted codon sets. To guide the design of
partly undefined (ambiguous) codon sets for these restricted li-
braries we employed structural information, the results of mul-
tiple sequence alignments, and knowledge from earlier rounds.
After five rounds of evolution with screening of only 5500
clones, we obtained two strongly diverged haloalkane dehalo-
genase variants that give access to (R)-epichlorohydrin with
90% ee and to (S)-epichlorohydrin with 97% ee, containing 13
and 17 mutations, respectively, around their active sites.
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generate NNS or NNK codons instead of the completely
random NNN codon in mutagenic primers.[5d]
In order to make a library that favors exploration of function-
al sequence space, it is possible to use further restricted
codons that specify subsets of the natural amino acids, also re-
ferred to as reduced amino acid alphabets.[12] Amino acid sub-
sets can be chosen such that libraries encompass large differ-
ences in physical and chemical properties of amino acids with-
out codon bias. Other options are to select sets of amino acids
on the basis of phylogenetic analysis, following the assump-
tion that substitutions that do not occur naturally are likely to
be poorly tolerated,[13] or to select reduced sets by use of
structural information,[15] or to use a database that includes
structural, genetic, and literature data.[14] Such smaller sets of
amino acids can be useful for controlling library size and might
also increase the abundance of desired phenotypes in a library.
In most directed evolution strategies, beneficial mutations
obtained from different libraries are combined. This can be
done by gene shuffling,[6b] staggered extension with recombi-
nation,[6c] and/or by using iterative cycles of mutagenesis.[7, 9]
Gene shuffling in the presence of synthetic oligonucleotides
can direct recombination to predetermined positions along
the protein sequence.[10] In these protocols, mutations discov-
ered in multiple variants rather than just the best variant are
included in templates or primers for a further round of muta-
genesis and screening. Through this process, functional diversi-
ty is maintained at key positions and combinations of muta-
tions that act synergistically might be found in later rounds.
Statistical methods can be used
to select beneficial mutations
for inclusion in the next round
of evolution.[17]
In the work described here
we have further explored a
number of the above considera-
tions to develop a strategy for
obtaining enantiocomplementa-
ry enzymes for conversion of a
toxic waste compound into a
useful optically active synthetic
intermediate. Enantiocomple-
mentary enzymes catalyze the
production or conversion of the
two enantiomers of a target
compound and thereby can
give access to both enantiomers
in pure or enriched form.[18] In
the case of asymmetric transfor-
mation of a prochiral substrate,
enantiocomplementary en-
zymes allow production of
either product enantiomer with
100% theoretical yield, whereas
a kinetic resolution has a maxi-
mum yield of only 50%. The
development of enantiocomple-
mentary enzymes has been ex-
amined for the production of optically active esters with the
aid of Baeyer–Villiger mono-oxygenases[19] and of hydroxyke-
tones with the aid of an aldolase,[20] as well as for asymmetric
reduction of ketones with the aid of enoate-reductases[21] and
enantioselective epoxidation of terminal alkenes with the aid
of cytochrome P450 BM3.[22] Directed evolution of enantiocom-
plementary enzymes for the conversion of meso-epoxides has
been investigated recently.[23]
The substrate explored here is 1,2,3-trichloropropane (TCP),
an industrial waste product that is toxic, extremely recalcitrant
to biodegradation, and expensive to dispose of by physical or
chemical methods.[24] A significant finding was that this prochi-
ral compound can be slowly converted hydrolytically by haloal-
kane dehalogenases.[25] The practical feasibility of such an en-
zymatic transformation would benefit from the product being
a useful compound instead of a waste product. We therefore
aimed to produce complementary enzymes that would convert
TCP into (R)- and (S)-2,3-dichloropropan-1-ol (DCP), which
would in turn give access to the chiral building blocks (R)- and
(S)-epichlorohydrin (Scheme 1). Both enantiomers of epichloro-
hydrin are valuable fine chemicals that find application in syn-
thetic routes to several pharmaceutical and healthcare prod-
ucts. DOV 102-677, which is under development by Merck for
the treatment of alcoholism, for example, is synthesized from
(R)-epichlorohydrin, whereas (S)-epichlorohydrin is a precursor
of the nutritional supplement l-carnitine,[26,27] the cholesterol-
reducing drug atorvastatin,[28] (R)-carvedilol, and b-aminoalco-
hols.[29]
Scheme 1. Desired enantioselective conversion of TCP into (R)- and (S)-2,3-dichloropropan-1-ol by enantiocomple-
mentary haloalkane dehalogenase variants. The products can be converted into epichlorohydrins with inversion
of configuration at their chiral centers under basic conditions.[26] Both epichlorohydrin enantiomers can be used
as intermediates for the production of chiral bioactive compounds.
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The haloalkane dehalogenases form a subclass of enzymes
in the a/b-hydrolase fold superfamily that cleave carbon-halo-
gen bonds.[30] Each is composed of a main domain and a cap
domain, with a catalytic pentad located between these do-
mains. The pentad is made up of an Asp-His-Asp catalytic triad
and a Trp-Trp or Trp-Asn diad for halide binding. An aspartate
residue acts as the nucleophile to displace a halide ion from
the substrate. By hydrolysis of the resulting covalent alkyl-
enzyme intermediate, alcohol is released. The only haloalkane
dehalogenases with demonstrated activity towards TCP are
variants of the enzyme from Rhodococcus rhodochrous
(DhaA).[25] The wild-type enzyme is widely distributed[31] but
has very low activity with TCP.[25a] At least three different direct-
ed evolution projects directed towards enhancement of its sta-
bility and activity have been carried out.[25a,b,c] The most active
mutant was found by Pavlova et al.[25c] and is referred to as
DhaA31. It contains five mutations and displays a 27-fold im-
provement in catalytic efficiency with TCP relative to the wild
type, but with a very low E value of 1.3 it would allow produc-
tion of (R)-2,3-dichloropropan-1-ol with an ee of only 13%.
Other haloalkane dehalogenases show large variations in enan-
tioselectivity towards chiral substrates, but the use of prochiral
substrates in asymmetric transformations is not well ex-
plored.[32]
To obtain enantiocomplementary enzymes for asymmetric
conversions of TCP, we set out to accomplish divergent evolu-
tion of haloalkane dehalogenase into variants selective for the
R and the S products with use of DhaA31 as the starting point.
The modest screening capacity offered by chiral gas chroma-
tography prompted us to use strategic considerations carefully
in library design throughout the directed evolution process.
Results and Discussion
Design of initial libraries and identification of hotspots
A number of high-throughput assays for screening of directed
evolution libraries for mutants with enhanced enantioselectivi-
ty have been developed.[33] However, because only a low-
throughput chiral GC assay was available for the screening of
DhaA variants capable of producing enantioenriched (R)- or
(S)-2,3-dichloropropan-1-ol from TCP, it was considered essen-
tial to construct libraries containing high frequencies of muta-
tions contributing to the desired phenotypes.
One way to increase the abundance of improved mutants in
a library is to focus mutagenesis on positions in the sequence
where, on the basis of the 3D structure, mutations would be
expected to influence the phenotype that should be modi-
fied.[7] Obviously, in cases in which the goal is a change in sub-
strate or product specificity, this is around the active site. A
molecular model of DhaA31 containing five mutations (I135F,
C176Y, V245F, L246I, Y273F) relative to the wild-type enzyme[25c]
was constructed with use of the published X-ray structure for
the wild-type enzyme as a template.[34] Inspection of the
model with TCP docked in the active site revealed that 16
amino acids not belonging to the catalytic pentad surround
the bound TCP (Figure 1). These first-shell noncatalytic posi-
tions were selected as targets for the first round of mutagene-
sis directed towards the production of variants for the forma-
tion of (R)-DCP and of (S)-DCP.
Another consideration in library design was the fact that
much larger numbers of different enzyme variants can be
tested with the same screening effort if repeated sampling of
identical clones is avoided. Comprehensive or deep screening
of libraries is always accompanied by extensive oversampling
(e.g. , fivefold to obtain 85% coverage of a two-site saturation
library[35]). This oversampling can be avoided through partial
screening of larger libraries or by screening multiple libraries in
parallel. We thus consider it inefficient to construct smaller
libraries just because it is easier to screen them completely. In
other words, as long as the abundances of desired mutants are
similar, it is preferable to omit genetic diversity at the screen-
ing step instead of at the library construction step, because
without oversampling a larger amount of sequence space can
be explored. The choice for partial screening of multiple pair-
wise libraries also has the advantage that possible synergistic
effects, which are known to be important in directed evolution,
are more intensively explored.[36]
For the first round of directed evolution we decided, on the
basis of the structural model with TCP docked in the active
site, to use oligonucleotide-assisted saturation mutagenesis for
the selected 16 active-site positions, combined in 14 partly
overlapping pair-wise libraries, which could be created with
standard QuikChange mutagenic PCR with use of NNS codon
degeneracy. Of the 16 positions, ten are represented in two
libraries, allowing thousands of different combinations that
could potentially have synergistic effects (Figure 2). The 16 se-
lected positions included sites discovered to be important for
TCP dehalogenase activity in earlier experiments.[25a,c] The total
number of possible variants in the combined libraries was
6400. From each library, 96 randomly picked variants were
tested for enantioselectivity and catalytic efficiency by chiral
GC, and many active clones with increased enantioselectivity
were found in different libraries (Figure 3). About 21% of the
sequence diversity represented in the pair-wise libraries was
tested and about 89% of the tested clones used for chiral GC
assays should be unique.
Figure 1. Structural model of DhaA31 with TCP (magenta) docked in the
active site. Catalytic residues are displayed in orange and the targeted first-
shell residues are displayed in turquoise.
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The results of the first round allowed the identification of
positions in the sequence at which mutations, either separately
or in combination, introduce significant enantioselectivity in
DhaA variants in the conversion of TCP. The results
also revealed positions at which mutations are detri-
mental for activity. In library 14, for example, only
2% of the clones were active, suggesting that most
mutations at either position in this library have neg-
ative effects on activity (Figure 3). Positions 273 and
274, which were those mutated in library 14, were
thus not included in the next round of mutagenesis.
The same holds for positions 132, 135, 149, 245, and
246, which did not yield variants with high enantio-
selectivity on mutation, even when tested in differ-
ent combinations. In contrast, mutations at positions
168, 172, and 176 occurred in different libraries in
which more than 40% of the mutants were active,
and many variants with significant R or S enantio-
selectivity were detected in these libraries (L7, L9;
Figure 3). These apparent hotspot positions were
promoted to the next round of mutagenesis and
screening. Positions 145, 206, and 209, of which the
last two had been tested only in a single pair-wise
library in round 1 and had also given positive hits,
were also promoted to round 2 and were subse-
quently tested in combinations with other positions.
The new combinations were made both by use of
templates with substitutions at positions 145, 206,
and 209 and primers with mutations at other posi-
tions, and by targeting of these positions with new
mutagenic primers in combinations with templates
substituted at other sites (Table 3, below). An exam-
ple of an interesting hotspot is position F168, located in an a-
helix close to the TCP binding site. In the best R-selective var-
iant F168 was mutated to a tryptophan (giving (R)-DCP with
an ee of 47%) whereas in the
best S-selective mutant (78% ee)
F168 was mutated to a cysteine,
indicating that different muta-
tions at the same position can
give opposite DCP enantiomers
as products.
Intensive exploration of muta-
tions at hotspots in new com-
binations
After enantioselectivity had
been observed in different DhaA
variants and hotspots had been
identified in the first round of
evolution (Figure 3), further im-
provement was sought through
more intensive exploration of
sequence diversity at these hot-
spots. To achieve further diver-
gence of R and S product enan-
tioselectivity, beneficial muta-
tions and influential sites were
retested in new combinations
Figure 2. Pair-wise mutant library design strategy. Round 1 used DhaA31 as template
(T1) ; both the 16 target positions selected on basis of the structure and the pair-wise
combinations are shown. Round 2 libraries are based on templates (T1, T3 for (R)-DCP se-
lectivity) or equimolar mixtures of templates (T4, T5, S selectivity) and promising target
positions found in round 1 in new pair-wise combinations. The E values of the templates
used for the second generation are indicated in brackets.
Figure 3. Screening results for 14 first-round mutant libraries. The product ee values (from 100% R to 100% S) are
displayed on the horizontal axes and the relative activities (conversion compared to wild type) are displayed on
the vertical axes. Dots indicate individual clones with measurable activity and enantioselectivity.
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through the construction of a second generation of pair-wise
site-saturation libraries. As templates we used not only individ-
ual plasmids with mutations but also mixtures of plasmids that
carried promising mutations as discovered in round 1 (e.g. , a
mixture of plasmids with P206A and P206V+L209F was used
in the template T5). New combinations of mutations that had
exhibited clear effects on enantioselectivity in round 1 (e.g. ,
F168+Y176 in library L21, Figure 2) were tested. In this way,
target sites were revisited in round 2 in even larger numbers
of combinations. High diversity was achieved in the libraries,
whereas the frequencies of inactive variants were kept low. A
total of seven libraries were constructed with 14 new combina-
tions of templates and target positions, giving a total library
size of 5600 possible variants (Figure 2).
To make optimal use of the limited screening capacity of the
chiral GC-based method, a prescreening assay for dehaloge-
nase activity was used, allowing removal of inactive variants
that might appear due to disruption of the integrity of the cat-
alytic site. In this pH indicator plate assay we used bromo-
ethane, which was selected because it is nonchiral and easily
converted by active haloalkane dehalogenases (because the
carbon-bromine bond in bromoethane is much easier to break
than the carbon-chlorine bond in TCP). Furthermore, bromo-
ethane has a low toxicity and viable cells can readily be recov-
ered from active colonies after exposure. Prescreening on pH
indicator plates increased the proportions of TCP-active clones
detected in subsequent GC assays to be 60–100%, depending
on the templates and primers that were used, whereas without
prescreening the proportions of TCP active clones were only
10–50%.
After prescreening and testing of product ee values by chiral
GC, several mutants with further improved enantioselectivity
were indeed found in this second round of directed evolution.
The best variants gave the R product with 60% ee and (S)-2,3-
dichloropropan-1-ol with an ee greater than 80%. The sequen-
ces of the eight variants that produced (S)-2,3-dichloropropan-
1-ol with ee>80% revealed
that these were based on a
template with position F168
changed either to leucine (six
out of eight) or to isoleucine
(two out of eight), whereas the
best first-generation clones had
contained the mutations F168C
or F168T. This shows that non-
optimal mutations can reappear
in different contexts in later
rounds of evolution, which is in
agreement with the occurrence
of synergistic effects observed
in other enzymes.[36] On the
other hand, even though fur-
ther improved S-enantioselec-
tive variants (up to 80% prod-
uct ees) were discovered in li-
braries that included the sites
P206 and L209, these positions
were discontinued because of the very low catalytic activities
in all libraries in which these positions were mutated, even
though they were tested in different combinations with other
positions. The observations show that promotion of multiple
beneficial mutations to a subsequent round of mutagenesis by
use of template mixtures is an efficient strategy for creating li-
braries with large numbers of different combinations of muta-
tions, which allows intensive exploration of parts of sequence
space in which synergetic effects can become manifest.
Revisiting first-shell residues in improved contexts by
restricted mutagenesis
The best R- and S-enantioselective variants that were obtained
after two rounds of evolution are all modified in an a-helix
that lines the active site (Figure 4). These were used as new
templates for further divergence. Improvement was sought by
mutagenesis of first-shell positions that had displayed modest
influences on enantioselectivity in the first round.
Because the earlier rounds had identified substitutions that
were not accepted in active variants, or only with low frequen-
cies, it was decided not to apply saturation mutagenesis, but
to introduce a specific restricted set of amino acids at each
target position (site-restricted mutagenesis, SRM). Furthermore,
rare codons, stop codons, and amino acid substitutions that
were expected on the basis of their positions in the structure
to influence expression or catalytic performance negatively (or
to abolish them entirely) were omitted when possible.
The restricted sets of amino acids were introduced with the
QuikChange oligonucleotide-assisted mutagenesis approach
with use of PCR primers that included partly undefined codons
at target sites (Table 1). At position 149, where only wild-type
phenylalanines appeared in first- and second-round hits, for
example, substitution was restricted to Phe and Tyr, which was
achieved with a partly undefined TWC codon (W stands for
A+T). Similarly, because multiple sequence alignments of hal-
Figure 4. Close-ups of the active sites of the best clones r2-60R (left) and r2-85S (right), after two rounds of evolu-
tion. Catalytic residues are in orange, mutated residues in green. Left : Best R-enantioselective variant with three
mutations (F168W+A172L+Y176G). TCP is docked in the active site in a configuration that leads to (R)-2,3-di-
chloropropan-1-ol formation. Right: Best S-enantioselective variant with different mutations at the same positions
(F168L+A172G+Y176L) and with TCP bound in a configuration that leads to S product formation. The positions
168, 172, and 176 presumably have a strong steric effect on the bound substrate in the active site. For modeling
see the Experimental Section.
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oalkane dehalogenases indicated restricted variation at posi-
tions 157 and 242, these were also tested with partly unde-
fined codons, with introduction of I157(I,L,F,M) and of
T242(T,S,N), respectively. Furthermore, some mutations that
had been encountered frequently— F246C and I246L, for ex-
ample—indicated that hydrophobic amino acids were pre-
ferred at certain positions in improved variants, so these sites
were targeted with oligonucleotides encompassing partly un-
defined codons that specifically cover hydrophobic residues. In
this way, five SRM libraries were constructed, each targeting
four sites and each containing approximately 280 possible var-
iants.
Obviously, most defined subsets of amino acids (there are
1048555 possible combinations of two to 20 natural amino
acids at a single site in a mutant library) cannot be covered
with a single partly undefined codon. Therefore, in several
cases mixtures of primers with partly undefined codons were
used during oligonucleotide-assisted mutagenesis, an example
of which is given in Table 1 for the W141(A,C,F,G,L,V,W,Y) re-
stricted mutagenesis. To facilitate the search for the best de-
fined (mixtures of) partly undefined codons that can be used
for efficient construction of these SRM libraries, search meth-
ods have been developed.[7c,16] We developed a codon search
algorithm (CoFinder) capable of finding both a suitable partly
undefined codon as well as mixtures of partly undefined
codons, with minimal codon bias and optimal avoidance of
undesired mutations in the library. The use of primer mixtures
with a different partly undefined codon at the same position
allows more precise coverage of a desired set of amino acids
than a single primer.
Screening of the SRM libraries designed to increase R enan-
tioselectivity resulted in several hits, of which the best variant
produced (R)-2,3-dichloropropan-1-ol with an ee that had been
improved from 60 to 75% (Table 2). The catalytic activity of
this third-generation variant was significantly enhanced relative
to its parent clone. The substitutions responsible for this im-
provement are F245Y and I246L. These are at positions that
were also targeted in library 12 during the first round of evolu-
tion, even though hardly any variants displaying altered enan-
tioselectivity had been observed in that library (Figure 3). This
again suggests that the effects of mutations are strongly con-
text-dependent and/or that functional sequence space was
more efficiently probed by SRM than by site-saturation muta-
genesis, because the frequency of beneficial variants is elevat-
ed.
In a library directed towards further enhancement of S enan-
tioselectivity, two variants that produced (S)-2,3-dichloropro-
pan-1-ol with ees of 90% were discovered, in relation to 80%
for the best round 2 variants. Also in these variants, I246 was
substituted with a leucine, hence representing reversion of a
DhaA31 mutation to the amino acid carried by the wild-type
DhaA at this site.
Although this revisiting of the first-shell sites in an improved
context by SRM resulted in the discovery of a few further im-
proved R- and S-enantioselective variants, screening of most
third-round libraries did not deliver mutants with enhanced
enantioselectivities, which suggests that the remaining first-
shell positions that were revisited in round 3 SRM libraries
Table 1. Example of a site-restricted mutagenesis (SRM) library based on
the use of partly undefined (ambiguous) codons.
Target position W141[a] A145 F149 F152
desired set of amino acids A,C,F,G,L,V,W,Y A,G,V F,Y C,F,L,W,Y
restricted codon primer 1 TDS[c] GBC[b] TWC[b] TDS[c]
encoded amino acids C,F,L,W,Y,* A,G,V F,Y C,F,L,W,Y,*
restricted codon primer 2 GBC[b] GBC TWC TDS
encoded amino acids A,G,V A,G,V F,Y C,F,L,W,Y,*
[a] Two mutagenic primers pairs were used in a 2:1 ratio to achieve the
desired set of substitutions at position 141. [b] Codes for partly undefined
bases: R=A+G; Y=C+T; M=A+C; K=G+T; S=C+G; W=A+T; B=
C+G+T; D=A+G+T; H=A+C+T; V=A+C+G; N=A+C+G+T.
[c] With the TDS codon degeneracy a stop codon (*) is also included, but
prescreening will discard clones with this mutation.
Table 2. Mutations in selected R- and S-enantioselective DhaA variants obtained in subsequent rounds of enantiodivergent directed evolution.
























































r1-47R 47 (R) W F
r2-60R 60 (R) W L G
r3-75R 75 (R) W L G Y L
r4-84R 84 (R) L T W L G Y L
r5-90R 90 (R) L T M W L I A G I N Y L T
S selectivity
r1-78S 78 (S) C L
r2-85S 85 (S) L G L
r3-90S 90 (S) L G L S L
r4-93S 93 (S) F I V A L G L S
r5-97S 97 (S) F M V D F R L G L I L W L A L V Y
[a] S= sheet, L= loop, H=helix. All mutations are in a DhaA31 background. [b] In the first column r# indicates the number of the round from which the
mutant is obtained.
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either do not contribute to enhanced enantioselectivity or do
so only in rare combinations with other amino acid substitu-
tions. Further divergence of the enzymes was therefore sought
at more distant sites.
Exploring distant residues with site-restricted mutagenesis
(SRM)
Engineering of enzyme enantioselectivity is often focused on
first-shell residues around the substrate-binding pocket, but
mutations at more distant positions can also have effects,
either through indirect interactions or by influencing protein
dynamics.[37] Further mutations that might enhance enantiose-
lectivity of DhaA variants were thus examined at a large
number of distant sites. A total of 52 positions located close to
the substrate binding pocket, either in the cap domain or in
the top part of the main domain, were selected on the basis of
structural inspection and phylogenetic analysis. Keeping in
mind that the modest screening capacity required the con-
struction of libraries with large representation of beneficial var-
iants, we used another round of site-restricted mutagenesis (I-
SRM, iterative site-restricted mutagenesis). The selection of re-
duced sets of amino acids for all target sites was inspired by
the natural diversity that was analyzed with the web tool Hot-
Spot Wizzard.[8,13] C128, which is located at the top part of the
main domain, for example, was mutated only to Cys or Phe,
whereas F131, positioned in a loop region connecting the
main domain with the cap domain, was mutated only to Phe,
Leu, Ile, and Met, because phylogenetic data suggested a
strong preference for hydrophobic residues at these positions.
With the help of CoFinder, primers for nine site-restricted li-
braries were designed for further enhancement of R selectivity
in round 4, with use of isolated plasmid DNAs of the best R-se-
lective hits of round 3 as templates. For further divergence in
the direction of S enantioselectivity, thirteen libraries were con-
structed with use of an equimolar mixture of plasmid DNAs
from the best S-selective variants available as templates. Four
to five sites were addressed in each library, and the libraries
were again screened in parallel.
Prescreening showed that the frequencies of active clones in
these round 4 libraries were fairly high (up to about 70%), indi-
cating either that the phylogeny- and structure-inspired site-re-
stricted mutagenesis indeed reduced the frequency of dysfunc-
tional mutants or that these distant positions were less critical
to enzyme activity. Several hits that displayed further enhanced
R or S enantioselectivity were discovered. In a library targeting
R enantioselectivity, a clone that produced 2,3-dichloropropan-
1-ol with an ee of 84% was found, in relation to 75% ee for
the best variant in the previous round. In another library, tar-
geting production of (S)-2,3-dichloropropan-1-ol, S enantiose-
lectivity was improved from 90 to 93% product ee. A shift in
the focus of mutagenesis from the first shell to more distant
locations thus indeed identified new positions that influenced
enantioselectivity and uncovered substitutions that gave fur-
ther improvement.
Final recombination of sites in consensus-based site-
restricted mutagenesis libraries
To improve the R and S enantioselectivities in the diverging
DhaA variants further, a fifth round of directed evolution was
conducted. All important potentially contributing substitutions
were now combined in a single library with simultaneous ex-
ploration of new genetic diversity through their occurrence in
different combinations. To reduce randomness during combi-
nation, we used a site-restricted mutagenesis protocol that
allows combinatorial incorporation of defined sets of substitu-
tions at multiple positions. The positions were ordered in short
regions that could each be covered either with a single
mutagenic oligonucleotide or with mixture of such mutagenic
oligonucleotides carrying several partly undefined codons
(Figure 5).
To select the influential positions and the preferred poten-
tially beneficial substitutions, 70 hits with improved enantiose-
lectivity, plus some variants with lower enantioselectivity from
the previous round, were sequenced. The identities of benefi-
cial mutations and their combined occurrences were deter-
mined by multiple sequence alignments and used in the
design of the round 5 libraries. These were constructed by con-
secutive rounds of QuikChange PCR reactions, which started
Figure 5. Combinatorial library design for the final round of directed evolu-
tion for S-product-selective haloalkane dehalogenase. Four hot regions, each
encompassing four to six influential positions, were subjected to site-restrict-
ed mutagenesis (SRM). For each position, a restricted set of amino acids was
selected on the basis of the mutants from previous rounds. Ten such earlier
mutants (H1–H10) are given here, together with their ee values. The restrict-
ed sets of amino acids were introduced by QuikChange PCR with use of oli-
gonucleotides or mixtures of oligonucleotides containing partly undefined
codons at the target positions. The first hot region, with segment C128-
R133 (boxed), for example, is modified to (C/F)ME(F/I/M)(V/I/A)(R/A). The
template sequence is the best hit of round 4 (r4-93S, Table 2), and is identi-
cal to DhaA31 in the region that is shown.
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with separate template mixtures prepared from earlier hits
that were S- or R-enantioselective.
For example, the template used in round 5 for further en-
hancing R enantioselectivity consisted of a mixture of four plas-
mids from round 4, each carrying seven or eight mutations. Re-
stricted mutagenic oligonucleotides were used in a combinato-
rial library design such that they covered different regions
along the protein sequence. To avoid accumulation of deleteri-
ous combinations of mutations, in each QuikChange round
one fifth of the template DNA was omitted from the PCR reac-
tion and added to the obtained PCR product before the subse-
quent QuikChange round that targeted the next hot region
was performed. By this approach, two different combinatorial
libraries for enhanced R and S enantioselectivity were con-
structed.
The combinatorial libraries used for S selectivity in round 5
again contained very high frequencies of active clones (about
80%), and this time almost 90% displayed better S enantio-
selectivity than the best earlier variant. This clearly shows that
the previous rounds of evolution and structural inspection had
indeed uncovered clusters in sequence space from which fur-
ther mutants could successfully be selected by testing new
combinations of mutations and using low-throughput chiral
GC screening. The best S-enantioselective variant produced (S)-
DCP with 97% ee (Figure 6, Table 2). A similar improvement
was observed with the constructed R-selective library, which
produced a clone that yielded (R)-DCP with 90% ee, significant-
ly better than the 84% ee of the best round 4 variant that was
found.
The best R- and S-selective hits that were found in the fifth
and final round of directed evolution carried 13 and 17 amino
acid substitutions, respectively. Most of these are located
around the substrate-binding pocket (Table 2, Figure 6). Some
mutations were found further away in the cap domain and in
the region where the main domain and cap domain make con-
tact. Interestingly, several highly contributing substitutions ap-
pearing in this round were present in loop regions in the top
part of the main domain and in a loop that connects the main
domain with the cap domain. The substitutions F135L+P136T
in the best R-selective variant and the substitutions E140D+
W141F in the best S-selective variant are located in this loop,
for example. Mutations in the connecting loop were also ob-
served in a laboratory evolution
experiment with the phyloge-
netically and structurally related
Xanthobacter autotrophicus hal-
oalkane dehalogenase.[39] Most
substitutions in the active sites
of the best R- and S-enantiose-
lective variants were located at
identical positions. However,
later substitutions appearing at
regions more distant from the
active site were found at differ-
ent positions in the R- and S-se-
lective mutants (Table 2).
Trajectory of divergent evolution
In five rounds of directed evolution, the enantioselectivity of
the DhaA variants diverged from 13% R product enantioselec-
tivity in the initial DhaA31 variant to 90% ee R product selec-
tivity for the DhaA variant r5-90R and 97% S enantioselectivity
for DhaA-r5-97S (Figure 7, Table 3). To determine the effects of
individual evolutionary rounds on the enantioselectivity we cal-
culated the contributions of the individual steps to the differ-
ences in transition state energy between the two reactions by
use of Equation (1). In this equation, D(R–S) DG
 is the difference
in transition state energy in comparison of conversion into (R)-
DCP and into (S)-DCP, ee has its usual meaning (0–1 scale), R is
the gas constant, and T is the absolute temperature.
Figure 6. Structural models of the final best enantiocomplementary DhaA
variants r5-90R and r5-97S. A) Variant with 13 mutations producing (R)-DCP.
B) Variant with 17 mutations producing (S)-DCP. The models show the mu-
tated amino acids in surface display revealing the wide distribution. Catalytic
residues are shown in yellow.
Figure 7. Schematic overview of the obtained evolutionary pathway.
Table 3. Contributions of individual evolutionary rounds to the differential transition state energies of the de-



















DhaA31 13 (R) 0.62 – DhaA31 13 (S) 0.62 –
r1-47R 47 (R) 2.63 28.8 r1-75S 75 (S) 5.02 49.4
r2-60R 60 (R) 3.57 13.5 r2-85S 85 (S) 6.48 12.8
r3-75R 75 (R) 5.02 20.7 r3-90S 90 (S) 7.59 9.8
r4-84R 84 (R) 6.30 18.4 r4-93S 93 (S) 8.55 8.4
r5-90R 90 (R) 7.59 18.6 r5-97S 97 (S) 10.8 19.6
The differences in transition state energies were calculated with Equation (1). The reported percentages are the
additional contributions that the new mutations in every round make to the transition state energy difference
in the final variants. Mutations in the best variants are given in Table 2.
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DðRSÞ DG
 ¼ ln 1þ ee
1ee  RT ð1Þ
The enantiodiscrimination must be based on differences in
binding energy and/or reactivity between the pro-S and pro-R
binding modes of TCP in the active site. This concept makes
the high enantioselectivity obtained in the mutants really im-
pressive, because the reaction does not take place at the pro-
chiral carbon atom and the enantiodivergent enzyme variants
have to discriminate between a hydrogen, a chlorine, and a
chloromethyl substituent to bind the substrate in a mode that
fits the appropriate product enantiopreference.
Eq. (1) can be used to analyze evolutionary landscapes.[38]
Both for R and for S enantioselectivity, the initial round contrib-
uted most to the evolution of the transition state energy differ-
ences that cause enantioselectivity (29 and 49%, respectively).
The two subsequent rounds, which targeted first-shell residues
in an improved context, contributed 34 and 23% to the final R
and S enantioselectivities. The last two rounds, in which distant
positions were addressed, contributed 37 and 28% to the free
energy differences for enhancing R and S selectivities. These re-
sults indicate that it is not only positions close to the active
site that are attractive targets for mutagenesis, but that posi-
tions more distant from the active site can also contribute con-
siderably to directed evolution of enantiocomplementary en-
zymes.
Catalytic properties of the best R- and S-enantioselective
variants
The best R- and S-enantioselective mutants that we found
(Table 3) were purified by His-tag Ni-agarose chromatography.
Both variants were >95% pure by SDS-PAGE and the kinetic
properties for TCP conversion were determined (Table 4). The
kcat values of both variants were lower than the kcat of DhaA31,
but approximately twice as high as the kcat of the wild-type
DhaA from which DhaA31 is evolved.[25d] The Km value of the
best R-selective clone was three times higher than that of the
wild-type DhaA, whereas the Km value of the best S-selective
variant was three times lower. The catalytic efficiencies of both
enantioselective variants were lower than the kcat/Km value of
the starting point DhaA31 (Table 4). Of the five amino acid sub-
stitutions that distinguish DhaA31 from wild-type DhaA, only
one and two substitutions remained unaltered in the two best
R- and S-enantioselective variants, respectively.
The stabilities of the best divergently evolved variants were
also tested. The wild-type DhaA displayed an apparent Tm of
49 8C as determined by thermofluor measurements and circular
dichroism. The corresponding values for the mutants were
determined by the thermofluor method and were 55, 51, and
57 8C for the mutants DhaA31, DhaA31-5r, and DhaA31-5s, re-
spectively, indicating that stability was hardly affected in either
of the highly mutated enzymes.
Conclusions
Directed evolution for obtaining improved biocatalysts often
requires time-consuming and expensive experimentation in-
volving multiple rounds of mutagenesis and screening. Al-
though various powerful approaches have been developed,
they might not be applicable in many cases. Especially if gene
expression procedures take very long, or if the target property
cannot be screened by high-throughput procedures, methods
that depend on testing large numbers of mutants or many
rounds of mutagenesis and screening will not be successful. In
this investigation we have developed strategies to design effi-
cient libraries that reduce screening efforts. A number of stra-
tegic considerations was incorporated in the approach that we
followed for directed evolution of enantiodivergent TCP-con-
verting haloalkane dehalogenases.
Firstly, unlike in most common protocols, we constructed li-
braries that encompassed multiple combinations of pair-wise
mutations around the active site. Obviously, this requires the
availability of structural information, for which we used a ho-
mology model built with a sequence containing five substitu-
tions relative to the wild-type template. The resulting libraries
were screened only partially, and nowhere was any attempt
made to reduce library size, which would be required for com-
plete or deep screening of the libraries, because the same
screening effort examines a much larger fraction of sequence
space when a large library (in our case encompassing multiple
combinations of mutations) is screened partially, in comparison
with the more or less comprehensive screening of a small li-
brary (which typically requires four- to sixfold oversampling for
a two-site saturation library for 90–95% coverage).
Secondly, to maintain functional genetic diversity during
evolution, we proceeded to next-generation libraries with mul-
tiple mutations and target sites from earlier hits by using both
template mixtures and primer mixtures in mutagenic PCR reac-
tions for library preparation. In this way, new mutations were
introduced in various combinations at two to five positions at
the same time, allowing diverse synergetic effects in the result-
ing libraries, and increasing the chances of discovery of benefi-
cial variants that are dependent on such synergetic effects. In
other words, individual rounds were more focused on identify-
ing influential positions than on the best mutations, because
these are very context-dependent anyway.
Thirdly, to increase the frequencies of positive variants in
mutant libraries, we restricted substitutions at target positions
to selected functional subsets of amino acids. These subsets
were identified by sequence data from earlier rounds, inspec-
tion of the three-dimensional structure of the enzyme, and
Table 4. Kinetic properties of divergently evolved DhaA variants.
Variant ee kcat [s
1] Km [mm] kcat/Km [m
1 s1]
DhaA31 13 (R) 1.26 1.2 1050
DhaA wild type 13 (R) 0.08 2.2 36
r5-90R 90 (R) 0.16 6.5 25
r5-97S 97 (S) 0.18 0.65 277
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phylogenetic analysis of homologous haloalkane dehalogenas-
es. The resulting site-restricted mutagenesis (SRM) libraries
were constructed with restricted ambiguous codon sets, which
were conveniently selected with a codon search algorithm (Co-
Finder) that will be described in detail elsewhere. To optimize
coverage of any desired set of amino acids at a specific posi-
tion in a library, CoFinder will suggest mixtures of primers,
each with a specific partly undefined (ambiguous codon), that
are used in the same mutagenic PCR reactions.
With these strategies we obtained enantiocomplementary
haloalkane dehalogenase variants that catalyze the asymmetric
conversion of TCP, a highly toxic industrial waste compound.
The structure of TCP means that it is a very challenging target,
because any enantioselectivity is caused by different binding
modes of this prochiral substrate in the transition state even
though TCP offers few interactions that restrict its active site
dynamics. The highly diverged variants that were obtained
after five rounds of evolution differ at 25 positions, yet were
discovered by chiral GC screening of just 5500 clones. The best
R- and S-enantioselective mutants carry 13 and 17 mutations,
respectively, relative to DhaA31, and produce the chiral build-
ing blocks (R)-2,3-dichloropropan-1-ol with 90% ee and (S)-2,3-
dichloropropan-1-ol with 97% ee. The approach followed here
thus appears to be an attractive strategy for directed evolution
of enantiodivergent enzymes for the conversion of prochiral
TCP. The approach might be also be useful for other enzymes
in which catalytic properties are governed by subtle differen-
ces in substrate positioning, especially if high-throughput ex-
pression or enzyme performance assays are unavailable.
Experimental Section
Molecular modeling : To predict the structure of mutated proteins
accurately, a computational protocol within YASARA (http://
www.yasara.org) was developed.[41] The protocol consists of six
rounds of optimization. In each round, the mutated side-chains are
energy-optimized in implicit water by sampling discrete side-chain
conformations (rotamers). This is followed by a gradient energy
minimization of the mutated side-chains and the nearby protein in
explicit water. Prior to prediction of the mutant DhaA structures,
TCP was docked in pro-R and pro-S orientations suitable for cataly-
sis into the template PDB file 1BN6[33,42] with the aid of Auto-
dock 4.0 as described earlier.[43,32b] Figures were prepared by use of
Pymol software (http://www.pymol.org).
Cultivation and expression : The dhaA31 gene[27c] was kindly pro-
vided by Prof. Jiri Damborsky (Masaryk University, Brno, Czech Re-
public). The gene was cloned with an N-terminal His6 tag in the
pBAD/Myc-His expression vector with use of NdeI and XhoI restric-
tion sites.[31b] The construct was transformed to and expressed in
E. coli XL10-Gold or TOP10. Cells were grown at 37 8C in liquid cul-
ture or on plates of Luria–Bertani (LB) medium supplemented with
ampicillin (50 mgmL1).
Library construction : All libraries were constructed by use of Quik-
Change Lightning single-site- or multi-site-directed mutagenic PCR
amplifications (Stratagene). Some modifications of the general pro-
tocol provided with the kit were made. DpnI digestion of parental
DNA was carried out at 37 8C over 40 min instead of 5 min and ul-
tracompetent cells of the strain XL10-Gold were directly trans-
formed with DpnI-digested PCR product (4 mL). Generally between
2103 and 8103 clones were obtained on a square LB+Amp
plate after overnight incubation at 37 8C. From the pooled colonies,
plasmid DNA was isolated and stored as library.
Library prescreening : Chemically competent E. coli TOP-10 cells
were transformed with library plasmid DNA and plated on pH indi-
cator plates for prescreening. Indicator plates contained eosin
(40 mgL1), methylene blue (6.5 mgL1), arabinose (200 mgL1),
and ampicillin (50 mgL1).[40] Hydrobromic acid production by indi-
vidual bacterial colonies could be detected after overnight growth
at 37 8C. For this, plates were incubated for 15 min at room tem-
perature after spotting of bromoethane (600 mL) on a filter paper
that was mounted in the lid of the plates. The plates were sealed
with parafilm and incubated in a fume hood. Bacterial colonies
expressing active haloalkane dehalogenase developed an intense
purple color, and cell material was immediately transferred to 96-
well plates containing LB medium (150 mL) plus ampicillin. After
overnight growth at 37 8C with shaking, glycerol (30 mL, 50%, v/v)
was added to each well and the plates were frozen at 80 8C and
stored at 20 8C until further use.
Screening for enantioselective TCP conversion : Deep-well 96
square well plates (polypropylene, Waters 186002482) containing
LB+amp liquid medium (200 mL) were inoculated from frozen
stocks by use of a pinned stamp (Enzyscreen). After 6 h of growth
at 37 8C under shaking conditions the log-phase cultures were
induced by addition of LB+Amp (1 mL) containing arabinose
(0.02%) and growth was allowed to continue under the same con-
ditions for 18 h. Pure TCP (3.5 mL) was then added directly to each
culture and the plates were capped and incubated for 5 h under
the same conditions. Both unreacted TCP and produced DCP were
extracted from the cultures with chloroform (220 mL) containing
dodecane (0.05%, v/v) as an internal standard. The organic layer
was carefully transferred to phase separation plates (Whatman 96-
well Unifilter 7720–7229–1) and the filtrate was collected in collec-
tion plates (Corning 3370) containing molecular sieves powder
(4 , 50 mg). Plates were sealed and incubated for 10 min under
shaking conditions and the drying agent was removed by centrifu-
gation at 2500g for 10 min at 16 8C. The chloroform extract was
transferred to polypropylene 96-deep-well plates (Greiner 780215)
containing glass inserts (300 mL, Waters 150820) and plates were
closed with aluminum seals.
For chiral GC we used a Shimadzu 17A dual-line GC with a PAL in-
jection system (CTC Analytics), an FID detector, and GC-solutions
software. Separation was performed with a Hydrodex-b-TBDAc
column, isothermic at 138 8C. Retention times were 1.83 min (TCP),
3.35 min ((R)-DCP) and 3.50 min ((S)-DCP). Samples from one plate
were injected with time intervals of 4.5 min and run in a single iso-
thermal run, allowing measurement of 384 samples in 24 h.
Thermostability : Thermal unfolding of mutant enzymes was moni-
tored by the fluorescence-based thermal stability method de-
scribed by Ericsson et al.[45] This method is based on a fluorescence
increase upon binding of Sypro Orange (Life Technologies, Carls-
bad, CA, USA) to hydrophobic protein surfaces that become ex-
posed during unfolding. Increases in fluorescence emission at
575 nm were monitored by excitation at 490 nm with a MyiQ real-
time PCR machine (Biorad) with increasing block temperatures
from 20 to 90 8C at 1 8Cmin1. Protein solutions containing 300-
fold diluted Sypro Orange (7.5 mL) in MilliQ water and purified pro-
tein (0.4 mgmL1, 17.5 mL) in TEMG buffer were prepared in iQ 96-
well real-time PCR plates. After sealing with iQ 96-Well PCR plate
seals (Biorad) the temperature gradient was started. The first deriv-
ative of the measured fluorescence change with temperature was
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calculated, giving the apparent melting temperature at the local
maximum.
Circular dichroism spectroscopy was carried out with a Jasco J-815
circular dichroism spectrometer and a 3 mL quartz cuvette. Protein
samples were dialyzed against potassium phosphate buffer
(pH 8.2, 10 mm) and diluted to about 0.2 mgmL1. The tempera-
ture was increased at a rate of 1 8Cmin1 and spectra from 260 to
200 nm were recorded every min. Displayed spectra are averaged
out of three recorded spectra. From plots of ellipticity versus tem-
perature, the temperature at which 50% of the protein was unfold-
ed (Tm,app) was derived by fitting a Boltzmann sigmoidal equation.
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